Solriamfetol could improve sleep measures

Multiple studies based on phase 3 clinical trials of the investigational drug solriamfetol have found that it may be effective for improving next-day wakefulness and work productivity in people with narcolepsy and obstructive sleep apnea, and that the drug can maintain its effect throughout the day as well as for up to 6 months. Also today, ankylosing spondylitis progression slowed when NSAIDs were added to TNFi, chronic kidney disease more common among patients with type 2 diabetes, laws that promote drug price transparency gain ground. Listen to the MDedge Daily News for today’s top news.